Early Clinical Trial Data and Real-world Assessment of COVID-19 Vaccines: Insights from the Society of Infectious Diseases Pharmacists

Overview

Journal Pharmacotherapy

Specialty Pharmacology

Date 2021 Oct 24

PMID 34689348

Citations 5

Authors

Nimish Patel

Jeannette Bouchard

Meredith B Oliver

Melissa E Badowski

Joseph J Carreno

Affiliations

Soon will be listed here.

Abstract

As of August 2021, there were three COVID-19 vaccines available in the United States for the prevention of coronavirus 2019 (COVID-19). The purpose of this narrative review is to examine the early experience from the Emergency Use Authorization (EUA) of BNT162b2 (Pfizer, Inc./BioNTech), mRNA-1273 (Moderna, Inc.), and Ad26.COV2.S (Johnson and Johnson/Janssen Global Services, LLC) through July 2021. The EUA data from the clinical trials have largely been corroborated by real-world effectiveness investigations post-authorization. These studies indicate that immunity is obtained within 2 weeks post-vaccination and may endure for 6 months. The immunity conferred by the vaccines may also be effective against SARS-CoV-2 variants of concern. Additionally, populations not included in the emergency use authorization studies may also benefit from vaccination. This look back at the initial clinical experience can be used by the global community to inform and develop COVID-19 vaccine programs.

Citing Articles

Health Consequences of University Employees Post-COVID-19 Vaccination at Palestinian Universities.

Shouli M, Ayed A, Shouli K, Issa B, Khraiwesh I SAGE Open Nurs. 2022; 8:23779608221144935.

PMID: 36582463 PMC: 9793012. DOI: 10.1177/23779608221144935.

Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.

Reyes-Leiva D, Lopez-Contreras J, Moga E, Pla-Junca F, Lynton-Pons E, Rojas-Garcia R Neurol Neuroimmunol Neuroinflamm. 2022; 9(4).

PMID: 35728947 PMC: 9219516. DOI: 10.1212/NXI.0000000000200002.

Prevalence of COVID-19 Infection among Patients with Diabetes and Their Vaccination Coverage Status in Saudi Arabia: A Cross-Sectional Analysis from a Hospital-Based Diabetes Registry.

Tourkmani A, Bin Rsheed A, AlEissa M, Alqahtani S, AlOtaibi A, Almujil M Vaccines (Basel). 2022; 10(2).

PMID: 35214769 PMC: 8878518. DOI: 10.3390/vaccines10020310.

Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?.

Parra-Lucares A, Toro L, Weitz-Munoz S, Ramos C Viruses. 2021; 13(12).

PMID: 34960761 PMC: 8708989. DOI: 10.3390/v13122493.

Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases Pharmacists.

Patel N, Bouchard J, Oliver M, Badowski M, Carreno J Pharmacotherapy. 2021; 41(10):837-850.

PMID: 34689348 PMC: 8662264. DOI: 10.1002/phar.2622.

References

Collier A, McMahan K, Yu J, Tostanoski L, Aguayo R, Ansel J . Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA. 2021; 325(23):2370-2380. PMC: 8120446. DOI: 10.1001/jama.2021.7563. View

Goyal M, Simpson J, Boyle M, Badolato G, Delaney M, McCarter R . Racial and/or Ethnic and Socioeconomic Disparities of SARS-CoV-2 Infection Among Children. Pediatrics. 2020; 146(4). DOI: 10.1542/peds.2020-009951. View

McMahan K, Yu J, Mercado N, Loos C, Tostanoski L, Chandrashekar A . Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2020; 590(7847):630-634. PMC: 7906955. DOI: 10.1038/s41586-020-03041-6. View

Tande A, Pollock B, Shah N, Farrugia G, Virk A, Swift M . Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular Screening. Clin Infect Dis. 2021; 74(1):59-65. PMC: 7989519. DOI: 10.1093/cid/ciab229. View

Marshall M, Ferguson I, Lewis P, Jaggi P, Gagliardo C, Collins J . Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics. 2021; 148(3). DOI: 10.1542/peds.2021-052478. View

Santoli J, Lindley M, DeSilva M, Kharbanda E, Daley M, Galloway L . Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration - United States, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(19):591-593. DOI: 10.15585/mmwr.mm6919e2. View

Keehner J, Horton L, Pfeffer M, Longhurst C, Schooley R, Currier J . SARS-CoV-2 Infection after Vaccination in Health Care Workers in California. N Engl J Med. 2021; 384(18):1774-1775. PMC: 8008750. DOI: 10.1056/NEJMc2101927. View

Villar J, Ariff S, Gunier R, Thiruvengadam R, Rauch S, Kholin A . Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021; 175(8):817-826. PMC: 8063132. DOI: 10.1001/jamapediatrics.2021.1050. View

Sheikh A, McMenamin J, Taylor B, Robertson C . SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397(10293):2461-2462. PMC: 8201647. DOI: 10.1016/S0140-6736(21)01358-1. View

10.

Rapaka R, Hammershaimb E, Neuzil K . Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials. Clin Infect Dis. 2021; 74(2):352-358. PMC: 7989512. DOI: 10.1093/cid/ciab213. View

11.

Wall E, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C . Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021; 397(10292):2331-2333. PMC: 8175044. DOI: 10.1016/S0140-6736(21)01290-3. View

12.

Feldstein L, Rose E, Horwitz S, Collins J, Newhams M, Son M . Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020; 383(4):334-346. PMC: 7346765. DOI: 10.1056/NEJMoa2021680. View

13.

Joseph N, Dude C, Verkerke H, Irby L, Dunlop A, Patel R . Maternal Antibody Response, Neutralizing Potency, and Placental Antibody Transfer After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Obstet Gynecol. 2021; 138(2):189-197. PMC: 8288196. DOI: 10.1097/AOG.0000000000004440. View

14.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

15.

Gee J, Marquez P, Su J, Calvert G, Liu R, Myers T . First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(8):283-288. PMC: 8344985. DOI: 10.15585/mmwr.mm7008e3. View

16.

Patel M, Jackson M, Ferdinands J . Postlicensure Evaluation of COVID-19 Vaccines. JAMA. 2020; 324(19):1939-1940. DOI: 10.1001/jama.2020.19328. View

17.

Abu-Raddad L, Chemaitelly H, Butt A . Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021; 385(2):187-189. PMC: 8117967. DOI: 10.1056/NEJMc2104974. View

18.

Saadat S, Tehrani Z, Logue J, Newman M, Frieman M, Harris A . Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA. 2021; 325(14):1467-1469. PMC: 7922233. DOI: 10.1001/jama.2021.3341. View

19.

. COVID-19 Vaccines in Children and Adolescents. Pediatrics. 2021; 148(2). DOI: 10.1542/peds.2021-052336. View

20.

Chia W, Zhu F, Ong S, Young B, Fong S, Bert N . Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021; 2(6):e240-e249. PMC: 7987301. DOI: 10.1016/S2666-5247(21)00025-2. View